Endocrine Abstracts

Introduction: In transsexualism, cross-sex hormone treatment (CHT) both improves and impairs several surrogate cardiovascular risk markers in female to male (FtoM). Few randomized trials on CHT with long follow-up and control group are available, and present evidence is inconsistent. We here assess changes in metabolic and cardiovascular risk after 12 months CHT compared with biological sex in FtoM GID.Methods: Prospective observational study, including ...